Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/056

Result Summary for 101468/056

Result Summary

Protocol ID:	101468/056
Clinical Study ID:	SKF 101468/056
Official Title:	A Double-blind, L-dopa Plus Benserazide Controlled, Multicentre Study of Ropinirole at a Flexible Oral Dose of 0.25 – 8 mg Three Times Daily for Five Years in the Treatment of Early Parkinsonian Patients Not Treated with L-Dopa.
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–1491